People: Concert Pharmaceuticals Inc (CNCE.OQ)

CNCE.OQ on NASDAQ Stock Exchange Global Market

1:30am IST
Change (% chg)

$-0.12 (-1.04%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Aldrich, Richard 

Mr. Richard H. Aldrich serves as Independent Chairman of the Board, Co-Founder of the Company. Mr. Aldrich is a co-founder of Concert and has served as a member of our Board and as Chairman of the Board since May 2006. Mr. Aldrich is a co-founder and was a Partner at Longwood Fund Management LLC, a venture capital firm, from December 2010 to December 2019. Mr. Aldrich has been an employee of Longwood Management LLC since August 2015. Mr. Aldrich founded RA Capital Management LLC, a hedge fund, in 2001 and served as a Managing Member from 2001 to 2008 and as a Co-Founding Member from 2008 to 2011. Mr. Aldrich has co-founded and helped to build several biotechnology companies including Sirtris Pharmaceuticals, Inc. (acquired by GlaxoSmithKline in 2008), Alnara Pharmaceuticals, Inc. (acquired by Eli Lilly in 2010), Verastem, Inc., OvaScience, Inc. and Flex Pharma, Inc. Mr. Aldrich was also a founding employee of Vertex Pharmaceuticals Incorporated, a pharmaceutical company, where he held the position of Senior Vice President and Chief Business Officer and managed all commercial and operating functions from 1989 to 2001. Prior to joining Vertex, Mr. Aldrich held several management positions at Biogen Inc. Mr. Aldrich also serves on the board of directors of a number of private biotechnology companies. During the last five years, Mr. Aldrich previously served on the board of directors of PTC Therapeutics, Inc. and OvaScience, Inc. Mr. Aldrich received a B.S. in Management from Boston College and an M.B.A. from the Amos Tuck School at Dartmouth College. We believe that Mr. Aldrich’s broad-based experience in business, including his leadership and board experience at life science companies, and his familiarity with our business as a co-founder of Concert make him a key contributor to our Board.

Basic Compensation

Total Annual Compensation, USD 83,518
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 74,074
Fiscal Year Total, USD 157,592

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Richard Aldrich


Roger Tung


Marc Becker


Nancy Stuart


James Cassella


Jeffrey Munsie

As Of  31 Dec 2019